Clinical Trials on Hodgkin's Disease in United Kingdom

Total 147626 results

Royal Marsden NHS Foundation Trust

Completed

A Retrospective Study of Toxicity and Outcome of High Dose Chemotherapy With Autologous Stem Cell Transplant in Patients With Non-Hodgkin Lymphoma (NHL).

Non-Hodgkins Lymphoma

United Kingdom
Spectrum Pharmaceuticals, Inc

Completed

Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease

Non-Hodgkins Lymphoma | Tumors | Hodgkins Disease

United States, Canada
Baylor College of Medicine
Center for Cell and Gene Therapy, Baylor College of Medicine

Recruiting

(TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL). (pediTACTAL)

Hodgkins Lymphoma | Non Hodgkins Lymphoma

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Terminated

Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin Disease (ANGELA)

Hodgkin Disease | Non-Hodgkins Lymphoma

United States
Genentech, Inc.

Completed

A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable

Non-Hodgkin's Lymphoma, Solid Cancers

United Kingdom
Weill Medical College of Cornell University

Completed

Health and Psychosocial Outcomes in Long-Term Lymphoma Survivors

Hodgkins Disease | Lymphoma, Non-Hodgkins

United States
Lymphoma Study Association

Unknown

Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma

Lymphoma

United Kingdom, France
Columbia University

Completed

Autologous and Allogeneic Transplant for Relapsed Lymphoma

Non-Hodgkin's Lymphoma | Hodgkins Disease

United States
The Christie NHS Foundation Trust

Terminated

A Phase I Study of CD19 Specific T Cells in CD19 Positive Malignancy (CD19)

CD19 Positive Non-Hodgkin Lymphoma

United Kingdom
European Organisation for Research and Treatment...
Stichting Hemato-Oncologie voor Volwassenen Nederland; Lymphoma Trials Office

Terminated

Chemotherapy Plus Interferon Alfa Alone or With Radiation Therapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma

Lymphoma

United Kingdom, Netherlands
Genentech, Inc.

Completed

A Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma, Solid Cancers

United States, United Kingdom, France
Indiana University

Terminated

Breast-Sparing Proton Therapy for Hodgkin's Disease (Breast Sparing)

Hodgkins Disease

United States
Medical Research Council

Completed

Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Disease

Lymphoma

United Kingdom
Gilead Sciences
Ono Pharmaceutical Co. Ltd

Completed

Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLL

Chronic Lymphocytic Leukaemia | Non Hodgkins Lymphoma

United Kingdom, France
Baylor College of Medicine
The Methodist Hospital Research Institute

Terminated

Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's Or Non-Hodgkin's Lymphoma (ALDI)

Non-Hodgkin Lymphoma | Hodgkins Lymphoma

United States
University of Nebraska
Schering-Plough

Completed

CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma

Non-Hodgkins Lymphoma

United States
Genentech, Inc.

Completed

A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma, Solid Cancers

United States, United Kingdom
United Kingdom Children's Cancer Study Group

Unknown

Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma

Lymphoma

United Kingdom
Astex Pharmaceuticals, Inc.

Terminated

Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma

Prostate Cancer | Non-Hodgkins Lymphoma

United Kingdom, United States
National Cancer Institute (NCI)

Terminated

Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders

Leukemia | Multiple Myeloma | MDS | Non-Hodgkins Lymphoma | Hodgkins Lymphoma

United States
Lymphoma Trials Office

Unknown

Rituximab Plus Combination Chemotherapy in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma

Lymphoma

United Kingdom
GlaxoSmithKline

Terminated

Evaluating the Utility of the Apoptosis Imaging Biomarker 18F]ML10 in Patients With Non-Hodgkin's Lymphoma(NHL)

Cancer

United Kingdom
Cancer Research Campaign Clinical Trials Centre

Completed

Combination Chemotherapy in Treating Older Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma

Lymphoma

United Kingdom
Scotland and Newcastle Lymphoma Group

Unknown

Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma

Lymphoma

United Kingdom
Fred Hutchinson Cancer Center
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Blood Samples to Evaluate Biomarkers of Donor Chimerism

Leukemia | Myelodysplastic Syndrome | Hodgkins Disease | Non-hodgkins Lymphoma

United States
ADC Therapeutics S.A.

Completed

Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma

Hodgkin Lymphoma | Non-Hodgkin Lymphoma

United States, United Kingdom
SCRI Development Innovations, LLC
Genentech, Inc.; Amgen

Completed

Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma

Non-Hodgkins Lymphoma

United States
University of Birmingham
Millennium Pharmaceuticals, Inc.; Leukaemia Lymphoma Research

Completed

A Study of Brentuximab Vedotin in Patients With Hodgkin Lymphoma Unsuitable for Chemotherapy Due to Age, Frailty or Co-morbidity (BREVITY)

Hodgkin Disease

United Kingdom
Novartis Pharmaceuticals
XOMA (US) LLC

Completed

Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies

Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma

United States, Belgium, Canada, Italy, France, Hong Kong, Australia, United Kingdom, Singapore, Korea, Republic of, Germany
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Open-Label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of VELCADE in Patients With Either Advanced Solid Tumors or Non-Hodgkin's Lymphoma.

Tumors | Non-Hodgkins's Lymphoma

United States
Pfizer

Terminated

Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS)

Hodgkins Lymphoma

United Kingdom, United States, Italy
Weill Medical College of Cornell University

Completed

Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma

Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma

United States
Genzyme, a Sanofi Company

Completed

A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma). (PREDICT)

Transplantation | Lymphoma (Non-Hodgkin's Lymphoma) | Hodgkin's Disease or Multiple Myeloma | Front Line Mobilization

Netherlands, France, Germany, Sweden, Spain, Italy, United Kingdom
Scotland and Newcastle Lymphoma Group

Unknown

Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Aggressive Non-Hodgkin's Lymphoma

Lymphoma

United Kingdom
Genzyme, a Sanofi Company

Completed

The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD)

Hodgkin Disease | Non-Hodgkin Lymphoma

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Active, not recruiting

EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma (CARCD30)

Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma

United States
University of Wisconsin, Madison
National Cancer Institute (NCI); Pfizer; Millennium Pharmaceuticals, Inc.

Completed

Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma

Non-Hodgkins Lymphoma

United States
Cortice Biosciences, Inc.

Completed

Study of TPI 287 in Patients With Advanced Malignancies

Neoplasms | Hodgkin Disease | Non-Hodgkin Lymphoma

United States
UNC Lineberger Comprehensive Cancer Center
Baylor College of Medicine; The Methodist Hospital Research Institute; Center...

Withdrawn

Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30)

Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma

United States
Bayer

Completed

Copanlisib Pharmacodynamic Study

Non Hodgkin Lymphoma

Belgium, France, United Kingdom
Cytokinetics

Completed

A Study of SB-743921 in Non-Hodgkin Lymphoma and Hodgkin Lymphoma

Non-Hodgkin's Lymphoma | Hodgkin's Disease

United States, Russian Federation
Burzynski Research Institute

Terminated

Antineoplaston Therapy in Treating Patients With High-Grade Stage II - Stage IV Non-Hodgkin's Lymphoma

Non-hodgkins Lymphoma

United States
Burzynski Research Institute

Terminated

Antineoplaston Therapy in Treating Patients With Intermediate-Grade Stage II - IV Non-Hodgkin's Lymphoma

Non-hodgkins Lymphoma

United States
King's College Hospital NHS Trust

Terminated

Pilot Study of Unrelated Cord Blood Transplantation

Lymphoma, Non-Hodgkin | Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Hodgkin Disease | Chronic Lymphocytic Leukemia | Leukemia, Lymphoblastic, Acute

United Kingdom
Genzyme, a Sanofi Company

Terminated

Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma

Non-Hodgkins Lymphoma

United States
Celgene Corporation
Prologue Research International

Completed

Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Non-Hodgkins Lymphoma

United States, Canada
Columbia University
Merck Sharp & Dohme LLC

Completed

Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies (SAHA)

Non-Hodgkin's Lymphoma | Hodgkin's Disease

United States
Cortice Biosciences, Inc.

Completed

Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies

Neoplasms | Non-Hodgkin's Lymphoma | Hodgkin's Disease

United States
West Virginia University
Kenyatta National Hospital

Withdrawn

Prospective Study of Lymphoproliferative Diseases

Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma

United States, Kenya
Menarini Group

Terminated

MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I Study (CD205SHUTTLE)

Metastatic Solid Tumors | Relapsed/Refractory Non-Hodgkin Lymphoma

Italy, Spain, Belgium, United Kingdom

Clinical Trials on Hodgkin's Disease in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations